Breast tissue organochlorine levels and metabolic genotypes in relation to breast cancer risk Canada

Cancer Causes and Control

Volumn 15, Issue 4, 2004, Pages 399-418

  McCready, David ^a   Aronson, Kristan J ^b   Chu, William ^c   Fan, Wenli ^b   Vesprini, Danny ^c   Narod, Steven A ^c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Breast cancer; Carcinogenesis; Genetics; Metabolism; Organochlorines

Indexed keywords

ORGANOCHLORINE DERIVATIVE;

ALLELE; ARTICLE; BODY BURDEN; BREAST ADENOMA; BREAST BIOPSY; BREAST CARCINOMA; CANCER INVASION; CANCER RISK; CANCER SUSCEPTIBILITY; CHEMICAL CARCINOGENESIS; COMPARATIVE STUDY; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METABOLIC ACTIVATION; PRIORITY JOURNAL; RISK ASSESSMENT;

ADULT; AGED; ALLELES; BREAST; BREAST NEOPLASMS; CARCINOGENS; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL POLLUTANTS; FEMALE; GENOTYPE; GLUTATHIONE TRANSFERASE; HUMANS; HYDROCARBONS, CHLORINATED; INSECTICIDES; MIDDLE AGED; ODDS RATIO; ONTARIO; RISK ASSESSMENT; RISK FACTORS; VARIATION (GENETICS);

EID: 3342917533     PISSN: 09575243     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:CACO.0000027505.32564.c2     Document Type: Article

References (45)

1. Narod SA (2002) Modifiers of risk of hereditary breast and ovarian cancer. Nature Rev Cancer. 2: 113-123.
2. Malkin D, Li FP, Strong LC, et al. (1990) Genuine p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science 250: 1233-1238.
3. Chevinex-Trench G, Spurdle AB, Gatei M, et al. (2002) Dominant negative ATM mutations in breast cancer families. J Natl Cancer Inst 6: 205-215.
4. Meijers-Heijboer H, van den Ouewland A, Klijn A. et al. (2002) Low penetrance susceptibility to breast cancer due to CHEK2(*) 1100delC in non-carriers of BRCA1 and BRCA2 mutations. Nat Genet 1: 55-59.
5. Cosma G, Crofts F, Taioli E, et al. (1993). Relationship between genotype and function of the human CYP1A1 gene. J Toxicol Environ Health 40: 309-316.
6. Drahushuk AT, Choy CO, Kumar S, Mcreynolds JH, Olson JR (1997) Modulation of cytochrome P450 by 5,5′bis-trinouromethyl-2-2′dichlorobiphenyl, a unique environmental contaminant. Toxicology 120: 197-205.
7. Huang CS, Chern HD, Chang KJ, et al. (1999) Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res 59: 4870-4875.
8. Rebbeck TM, Rosvold EA, Duggan DJ, et al. (1994) Genetics of CYP1A1: coamplification of specific alleles by polymerase chain reaction and association with breast cancer. Cancer Epidemiol Biomark Prev 3: 511-514.
9. Ambrosone CB, Freudenheim JL, Graham S, et al. (1995) Cytochrome P4501A1 and glutathione s-transferase (M1) genetic polymorphisms and postmenopausal breast cancer risk. Cancer Res 55: 3483-3485.
10. Huang CS, Shen CY, Chang KJ, et al. (1999) Cytochrome P4501A1 polymorphism as a susceptibility factor for breast cancer in postmenopausal Chinese women in Taiwan. Brit J Cancer 80: 1838-1843.
11. Landi MT, Sinha R, Lang NP, Kadlubar FF (1999) Human cytochrome P4501A2. IARC Scientific Publications (148), pp. 173-195.
12. Nakajima M, Yokoi T, Mizutani M, et al. (1999) Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on CYP1A2 inducibility in humans. J Biochem 4: 803-808.
13. Guengerich FP, et al. (1986) Characterization of rat and human liver micorsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 261: 5051-5060.
14. Guengerich FP (1988) Oxidation of 17 alpha-ethynylestradiol by human liver cytochrome P-450. Mol Pharmacol 33: 500-508.
15. Bork RW, et al. (1989) Characterization of mRNA species related to human liver cytochrome P-450 nifedipine oxidase and the regulation of catalytic activity. J Biol Chem 264: 910-919.
16. Hukkanen J, et al. (1998) Expression of cytochrome P450 genes encoding enzymes active in metabolism of tamoxifen in human uterine endometrium. Pharmacol Toxicol 82: 93-97.
17. Rebbeck T. R, et al. (1998) Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 90: 1225-1229.
18. Spurdle AB, Goodwill B, Hodgson E, et al. (2002) The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. Pharmacogenetics 5: 355-366.
19. Amirimani B, Walker AH, Weber BL, Rebbeck TR (1999) RESPONSE: re modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 91: 1588-1590.
20. Raunio H, Husgafvel-Pursiainen K, Anttila S, et al. (1995) Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility: a review. Gene (Amst) 159: 113-121.
21. Seidegard J, Pero RW, Markowitz MM, et al. (1990) Isoenzymes of glutathione transferase (class μ) as a marker for the susceptibility to lung cancer: a follow-up study. Carcinogenesis (Lond.) 11: 33-36.
22. Bailey LR, Roodi N, Verrier CS, et al. (1988) Breast cancer and CYP1A1, G-STM1, and GSTT1 polymorphisms: Evidence of a lack of association in Caucasians and African Americans. Cancer Res 58: 65-70.
23. Garcia-Closas M, Kelsey KT, Hankinson HE, et al. (1999) Glutathione s-transferase mu and theta polymorphisms and breast cancer susceptibility. J Natl Cancer Inst 91: 1960-1964.
24. Curran JE, Weinstein SR, Griffiths LR (2000) Polymorphisms of glutathione s-transferase genes (GSTM1, GSTP1 and GSTT1) and breast cancer susceptibility. Cancer Lett 153: 113-120.
25. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (1976) IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemical to Humans: polychlorinated Biphenyls and Polybrominated Biphenyls, Vol. 18. Lyon, France: IARC.
26. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (1987) IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans: overall Evaluations of Carcinogenicity: an Updating of IARC Monographs, Vol. 1-42 (Suppl. 007). Lyon, France: IARC.
27. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (1991) IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans: occupational Exposures in Insecticide Application, and Some Pesticides, Vol. 53. Lyon, France: IARC.
28. Woolcott CG, Aronson KJ (2001) Organochlorines: a Metaanalysis. In: review of Lifestyle and Environmental Risk Factors for Breast Cancer: report of the Working Group on Primary Prevention of Breast Cancer. Health Canada (ISBN 0-662-30817-4).
29. Laden FG, Collman G, Iwamoto K, et al. (2001) 1,1-dichloro-2,2-bis(p- chlorophenyl)ethylene and polychlorinated biphenyls and breast cancer: combined analysis of five US Studies. J Natl Cancer Inst 93: 768-775.
30. Moysich KB (2001) Research commentary: thoughts on recent findings regarding organochlorines and breast cancer risk. The Ribbon 6: 5-6.
31. Aronson KJ, Miller AB, Woolcott CG, et al. (2000) Breast adipose tissue concentrations of polychlorinated biphenyls and other organochlorines and breast cancer risk. Cancer Epidemiol Biomark Prev 9: 55-63.
32. Woolcott CG, Aronson KJ, Hanna WM, et al. (2001) Breast cancer risk and organochlorines by receptor status, tumor size and grade. Cancer Causes Control 12: 395-404.
33. Demers A, Ayotte P, Brisson J, Dodin S, Robert J, Dewailly E (2002) Plasma concentrations of polychlorinated biphenyls and the risk of breast cancer: a congener-specific analysis. Am J Epidemiol 155: 629-635.
34. Hayashi SI, Watanabe J, Nakachi K, Kawajiri K (1991) PCR detection of an A/G polymorphism within exon 7 of the CYP1A1 gene. Nucleic Acids Res 19: 4797.
35. Cascorbi I, Brockmoller J, Roots I (1996) A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res 56: 4965-4969.
36. Park JY, Muscat JE, Ren O, et al. (1997) CYP1A1 and GSTM1 polymorphisms and oral cancer risk. Cancer Epidemiol Biomarkers Prev 10: 791-797.
37. Safe S (1989) Polychlorinated biphenyls (PCBs): mutagenicity and carcionogenicity. Mutat Res 224: 79-88.
38. Korytko PJ, Casey AC, Bush B, Quimby FE (1999) Induction of hepatic cytochromes P450 in dogs exposed to a chronic low dose of polychlorinated biphenyls. Toxocol Sci 47: 752-761.
39. Helzlsouer KJ, Alberg AJ, Huang HY, et al. (1999) Serum concentrations of organochlorine compounds and the subsequent development of breast cancer. Cancer Epidemiol Biomarkers Prev 8: 525-532.
40. Suchar La, Chang RL, Thomas PE, Rosen RE, LechConney AH (1996) Effects of phenobarbitol, dexamethasone and 3′ methylcholanthrene administration on the metabolism of 17-β estradiol on liver microsomes from female rats. Endocrinology 137: 663-667.
41. Oysich KB, Shields PG, Freudenheim JL, et al. (1999) Polychlorinated biphenyls, cytochrome P4501A1 polymorphism, and postmenopausal breast cancer risk. Cancer Epidemiol Biomark Prev 8: 41-44.
42. Laden F, Ishibe N, Hankinson SE, et al. (2002) Polychlorinated biphenyls, cytocohrome 4501A1 and breast cancer risk in the Nurses Health Study. Cancer Epidemiol Biomark Prev 11: 1560-1565.
43. Adami HO, Lipworth L, Titus-Ernstorff L, et al. (1995) Organochlorine compounds and estrogen-related cancers in women. Cancer Causes Control 6: 551-566.
44. Davidson EN, Yager JD (1997) Pesticides and breast cancer: fact or fad? J Natl Cancer Inst 89: 1743-1744.
45. Deutch B, Hansen JC (2000) High human plasma levels of organochlorine compounds in Greenland. Regional differences and lifestyle effects. Danish Med Bull 47: 13207.